Search
Loading Complete
Kenneth Cohen

Kenneth Cohen, MD, MBA

Pediatric Medical OncologyNeuro-OncologyPediatric Neuro-Oncology

Accepting New Patients

Highlights

Age Groups Seen

  • Infant 0-2
  • Child 3-12
  • Adolescent 13-17
  • Young Adult 18-25

Languages

  • English

In-Network Plans

View All Accepted Plans (12)

Gender

Male

Johns Hopkins Affiliations:

  • Johns Hopkins School of Medicine Faculty

About Kenneth Cohen

Professional Titles

  • Clinical Director Pediatric Oncology
  • Director, Pediatric Neuro-Oncology
  • Director, Strategic Planning, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Primary Academic Title

Professor of Oncology

Johns Hopkins Physician

Logo for Johns Hopkins Physician

Background

Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center (SKCCC)at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas.  He serves on the scientific advisory board for numerous foundations and companies.  He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. 

Dr. Cohen, in his role as the Director, Strategic Partnerships for the SKCCC is responsible for planning, developing and maintaining strategic integration of cancer services and relationships with existing and potential SKCCC programs and partners. This position is designed to create a cohesive system of services and offerings that will extend the expertise of the SKCCC locally, nationally and internationally.  In this role, he provides medical expertise to assure that integrated relationships benefit cancer patients, education and research.

Centers and Institutes

Clinical Trial Keywords

Pediatric brain tumors, Neuro-Oncology

Find a Clinical Trial

View all trials by this principal investigator.

Additional Academic Titles

Professor of Pediatrics

Research Interests

Early-phase drug development for high-risk pediatric brain tumors

Research Summary

More children die of brain tumors than of any other type of pediatric cancer. Significant advances have been made in surgical and supportive care but with fewer evident therapeutic benefits. Dr. Cohen's clinical research focuses on the application of new therapeutics in children with high-risk brain tumors, with a particular focus on children with high-grade gliomas.

PubMed - Publications

https://www.ncbi.nlm.nih.gov/myncbi/14WanmyMGun5v/bibliography/public/

Selected Publications

  • Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL. Temozolomide in the treatment of high-grade gliomas in children; a report from the Children’s Oncology Group.  Neuro Oncol. 2011 Mar;13(3):317-23

  • Cooney TM, Cohen KJ*, Guimaraes CV, Dhall G, Leach J, Massimino M, Erbetta A, Chiapparini L, Malbari F, Kramer K, Pollack IF, Baxter P, Laughlin S, Patay Z, Young Poussaint T, Warren KE. Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 Jun;21(6):e330-e336

  • Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, André N, Hansford JR, Hassall T, Eyrich M, Gururangan S, Bartels U, Gajjar A, Howell L, Warad D, Pacius M, Tam R, Wang Y, Zhu L, Cohen K. Nivolumab With or Without Ipilimumab in Pediatric Patients With High-Grade CNS Malignancies: Safety, Efficacy, Biomarker, and Pharmacokinetics: CheckMate 908. Neuro Oncol. 2023 Feb 20:

  • Naung H, Cohen KJ. An intrathecal limited postoperative chemotherapy regimen for the treatment of young children with nodular/desmoplastic medulloblastoma and medulloblastoma with extensive nodularity. J Neurooncol. 2021 May;152(3):567-572

  • Bouffet E, Hansford JR, Garrè ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023 Sep 21;389(12):1108-1120

Memberships

  • American Society of Clinical Oncology
  • American Society of Pediatric Hematology/Oncology
  • Society for Neuro-Oncology

Locations

  1. Johns Hopkins Children's Center

Expertise

Education

  • Medical Education: SUNY Upstate Medical University, MD, 1987

Board Certifications

  • Pediatric Hematology-Oncology: American Board of Pediatrics, 1994

Insurance

Please contact the location directly to confirm your health plan is accepted.
Search plans
  • Aetna
  • CareFirst
  • Cigna
  • First Health
  • Geisinger Health Plan
  • HealthSmart/Accel
  • Johns Hopkins Health Plans
  • MultiPlan
  • Pennsylvania's Preferred Health Networks (PPHN)
  • Point Comfort Underwriters
  • Private Healthcare Systems (PHCS)
  • Veteran Affairs Community Care Network (Optum-VACCN)